Daily Endocrinology Research Analysis
Three impactful endocrinology papers stand out today: a Cell study uncovers a microbiome-derived bile acid (Trp-CA) that improves glucose homeostasis via the orphan GPCR MRGPRE, a meta-regression across 41 antidiabetic RCTs quantifies that body weight and systolic blood pressure reductions dominate cardiovascular risk improvement, and a multicenter position statement defines benchmark outcome metrics for endoscopic pituitary surgery in Cushing’s disease. Together, they advance mechanistic unders
Summary
Three impactful endocrinology papers stand out today: a Cell study uncovers a microbiome-derived bile acid (Trp-CA) that improves glucose homeostasis via the orphan GPCR MRGPRE, a meta-regression across 41 antidiabetic RCTs quantifies that body weight and systolic blood pressure reductions dominate cardiovascular risk improvement, and a multicenter position statement defines benchmark outcome metrics for endoscopic pituitary surgery in Cushing’s disease. Together, they advance mechanistic understanding, clarify risk-mediation in diabetes care, and standardize surgical quality metrics.
Research Themes
- Microbiome–host signaling in metabolic control
- Risk-mediation of cardiovascular outcomes in diabetes therapy
- Standardized surgical outcome metrics in pituitary endocrinology
Selected Articles
1. A microbial amino-acid-conjugated bile acid, tryptophan-cholic acid, improves glucose homeostasis via the orphan receptor MRGPRE.
This study identifies tryptophan-conjugated cholic acid (Trp-CA) as a microbiome-derived bile acid reduced in type 2 diabetes, inversely associated with glycemic markers, and capable of improving glucose tolerance in diabetic mice. Trp-CA directly activates the orphan GPCR MRGPRE, engaging Gs–cAMP and β-arrestin-1–ALDOA signaling. Bifidobacterium enzymes generate Trp-CA, highlighting a tractable host–microbe metabolic axis.
Impact: Deorphanizing MRGPRE with a human-relevant microbial bile acid and demonstrating glucose benefits establishes a novel metabolic signaling pathway with therapeutic potential for type 2 diabetes.
Clinical Implications: While preclinical, the work nominates MRGPRE as a drug target and supports strategies such as MRGPRE agonists or microbiome-based augmentation of Trp-CA production to improve glycemic control.
Key Findings
- Trp-CA is significantly decreased in patients with type 2 diabetes and negatively correlates with glycemic markers.
- Trp-CA improves glucose tolerance in diabetic mouse models.
- MRGPRE is identified as a receptor for Trp-CA, with defined binding mode.
- Both MRGPRE–Gs–cAMP and MRGPRE–β-arrestin-1–ALDOA pathways mediate metabolic benefits.
- Bifidobacterium bile salt hydrolase/transferase activity produces Trp-CA.
Methodological Strengths
- Mechanistic deorphanization of a GPCR with ligand–receptor binding mode elucidation.
- Multi-system validation linking human association data to in vivo efficacy in diabetic mice.
Limitations
- Human data are correlative; causality and effect size in humans remain unproven.
- Safety, pharmacokinetics, and tissue-specific MRGPRE signaling in humans are not characterized.
Future Directions: Develop selective MRGPRE agonists, test Trp-CA or analogs in early-phase clinical trials, and engineer microbiome strategies to elevate endogenous Trp-CA.
Recently, microbial amino-acid-conjugated bile acids (MABAs) have been found to be prevalent in human samples. However, their physiological significance is still unclear. Here, we identify tryptophan-conjugated cholic acid (Trp-CA) as the most significantly decreased MABA in patients with type 2 diabetes (T2D), and its abundance is negatively correlated with clinical glycemic markers. We further demonstrate that Trp-CA improves glucose tolerance in diabetic mice. Mechanistically, we find that Trp-CA is a ligand of the orphan G protein-coupled receptor (GPCR) Mas-related G protein-coupled receptor family member E (MRGPRE) and determine the binding mode between the two. Both MRGPRE-Gs-cyclic AMP (cAMP) and MRGPRE-β-arrestin-1-aldolase A (ALDOA) signaling pathways contribute to the metabolic benefits of Trp-CA. Additionally, we find that the bacterial bile salt hydrolase/transferase of Bifidobacterium is responsible for the production of Trp-CA. Together, our findings pave the way for further research on MABAs and offer additional therapeutic targets for the treatment of T2D.
2. The Contributions of Risk Factor Modifications to the Reduction of Cardiovascular Risk in Patients With Antidiabetic Treatment: A Meta-Regression Analysis and Model-Based Analysis.
Across 41 antidiabetic RCTs, meta-regression and model-based analyses indicate that reductions in body weight and systolic blood pressure are the dominant contributors to lowering MACE, CV death, MI, stroke, and heart failure hospitalizations, exceeding contributions from HbA1c changes. Treatment-response factors outperformed baseline factors in explaining risk reductions.
Impact: Quantitatively prioritizing weight and blood pressure reduction as key mediators of cardiovascular benefit reframes therapeutic goals in diabetes beyond glycemic control alone.
Clinical Implications: In selecting antidiabetic therapies and adjunctive care, prioritizing agents and strategies that reduce body weight and systolic blood pressure may yield larger cardiovascular benefits than focusing on HbA1c alone. This supports integrated management (e.g., lifestyle, antihypertensives, weight-lowering antidiabetic agents).
Key Findings
- Among treatment-response factors, 5-kg weight loss and 5-mmHg SBP reduction explained substantial reductions in MACE, CV death, MI, stroke, and HHF.
- HbA1c changes contributed less to cardiovascular risk reduction than weight and SBP changes.
- Treatment-response factors explained risk reduction better than baseline characteristics.
Methodological Strengths
- Meta-regression across 41 RCTs with complementary model-based analysis.
- Simultaneous evaluation of multiple treatment-response and baseline factors.
Limitations
- Study-level meta-regression is susceptible to ecological bias and residual confounding.
- Unexpected associations (e.g., higher baseline weight linked to reduced risk) suggest potential selection or modeling artifacts; individual patient data were not analyzed.
Future Directions: Conduct individual patient data meta-analyses and prospective mediation studies to validate the relative contributions of weight and SBP changes and to refine risk-based treatment selection.
AIMS: This meta-regression analysis and model-based analysis aimed to assess the contributions of the risk factors and identify the predominant ones. METHODS: PubMed/MEDLINE, Embase, and Cochrane databases were searched for randomized controlled trials with reports of cardiovascular events in patients receiving antidiabetic treatments. Five treatment-response factors such as changes in haemoglobin A1c (HbA1c), systolic blood pressure (SBP), body weight, low-density lipoprotein cholesterol (LDL-C) and estimated glomerular filtration rate (eGFR), and six baseline factors such as HbA1c, SBP, body weight, LDL-C, eGFR and age were included in the analyses. Eligible data were first analysed by a meta-regression analysis and then by a mathematical model-based analysis. RESULTS: In all 41 studies were included. Among all treatment response factors, reduction in body weight and SBP were key factors in lowering cardiovascular risk. A 5-kg body weight reduction accounted for 5%, 33%, 11.6%, 13% and 31.2% risk reduction in MACE, CV death, MI, stroke, and HHF, respectively. A 5-mmHg SBP reduction contributed 42.3%, 34.9%, 38.5%, 11% and 21.4% to the risk reduction in MACE, CV death, MI, stroke and HHF, respectively. Among all baseline factors, an increase in the baseline body weight was the main contributor to cardiovascular risk reduction. A 5-kg increase in baseline body weight was associated with 12.5%, 3.5%, 6.5% and 8.4% risk reduction in MACE, CV death, MI, and stroke, respectively. CONCLUSION: The reduction in body weight and SBP level were the dominant contributors to cardiovascular risk reduction among all 11 included potential factors. The treatment response factors might be more crucial to reduce cardiovascular risk when compared with baseline factors.
3. Outcome metrics for primary endoscopic endonasal surgery for low-risk patients with Cushing's disease: an evidence-based position statement from the Registry of Adenomas of the Pituitary and Related Disorders consortium.
Using data from 12 US pituitary centers (n=431), the RAPID consortium proposes benchmark metrics for low-risk Cushing’s disease surgery: 1-year sustained remission 81.2% (92.2% at 75th percentile), postoperative CSF leak 1.3% (<1% at 75th percentile), mean length of stay 3.8 midnights (3.0 at 75th percentile), readmission 11.1% (6.3% at 75th percentile), and very low permanent AVP deficiency (1.8%).
Impact: Provides actionable, multicenter, evidence-based targets for surgical quality improvement in a high-morbidity endocrine disorder.
Clinical Implications: Centers can benchmark remission, complications (e.g., CSF leak, AVP deficiency), readmissions, and length of stay to optimize pathways, inform patient counseling, and drive quality initiatives.
Key Findings
- In 431 primary endoscopic surgeries, 1-year sustained remission was 81.2%; postoperative CSF leak rate was 1.3%.
- Mean length of stay was 3.8 midnights and 90-day unplanned readmission was 11.1%; disposition to skilled nursing was 2.2%.
- 75th percentile benchmarks by center: remission 92.2%, CSF leak <1%, LOS 3.0 midnights, readmission 6.3%, and AVP deficiency <1% (permanent and temporary).
Methodological Strengths
- Multicenter dataset with predefined low-risk cohort and standardized outcome reporting.
- Provides both mean performance and 75th percentile targets to guide quality improvement.
Limitations
- Observational benchmarking without randomized comparisons; practice variations may affect metrics.
- Generalizability limited to low-risk, primary surgery populations in US centers.
Future Directions: Validation in broader risk groups and international cohorts, integration into registry-based quality dashboards, and linkage of process measures to outcome targets.
OBJECTIVE: Reports of surgical outcomes for Cushing's disease are mostly limited to single-center experiences by expert surgeons. Therefore, no generalizable surgical outcome metrics for endoscopic endonasal Cushing's disease surgery are available for practitioners to guide quality-improvement efforts. This is potentially problematic, given the high morbidity and excess mortality observed in patients who do not achieve remission. This study proposes a bundle of evidence-based metrics for low-risk patients with Cushing's disease, for whom optimal outcomes would be expected, that focus on the cost efficiency of care and surgical outcomes from multicenter collaboration of US pituitary centers. METHODS: The steering committee of the Registry of Adenomas of the Pituitary and Related Disorders (RAPID) consortium proposed the metrics based on available data from 12 US pituitary centers. A benchmarking population of low-risk patients undergoing first-time surgery was identified. Patient characteristics and outcomes were aggregated and analyzed by a data coordinating center. Metrics were reported using 2 approaches. RESULTS: A total of 431 patients from 12 centers who underwent primary endoscopic transsphenoidal surgery from January 1, 2006, to December 31, 2022, were included. There were 227 patients in the low-risk cohort (age < 70 years, BMI < 50, microadenoma, and Knosp grade 0-2). For the cost-efficiency metrics, the mean (SD) length of stay was 3.8 (4.8) midnights, and the percentage of patients readmitted was 11.1%. The rate of disposition to a skilled nursing facility was 2.2%. For surgical outcomes, the rate of postoperative CSF leakage was 1.3%, and the rate of 1-year sustained surgical remission was 81.2%. The rates of permanent and temporary arginine vasopressin deficiencies were 1.8% and 11.9%, respectively. The 75th percentile performance by center was 3.0 midnights for length of stay, 6.3% for 90-day unplanned readmission, < 1% for disposition to a skilled nursing facility, < 1% for CSF leakage, and 92.2% for 1-year sustained remission. The 75th percentile was < 1% for both permanent and temporary arginine vasopressin deficiencies. CONCLUSIONS: An evidence-based bundle of metrics in a Cushing's disease patient population at low risk who underwent first-time endoscopic pituitary surgery is proposed. Surgeons can use these metrics to assess and improve the quality of their clinical pathways.